Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Incyte Corporation — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 7.1× Incyte Corporation's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Incyte Corporation for 33 Days on average.
| IEMG | INCY | |
|---|---|---|
Market Cap | $162.00B | $22.85B |
Volume | 13,446,151 | 1,927,029 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $129.93 |
52-Week Low | $64.22 | $83.80 |
Typical Hold Time | 57 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.29, down 0.91% with bearish technical signals dominating. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers and its appeal for long-term portfolio strategies despite higher volatility compared to developed market alternatives.
The outlook remains cautious given technical weakness, though emerging market exposure offers growth potential. Key risks include sector concentration in technology and emerging market volatility. Analyst comparisons favor IEMG for cost efficiency and performance, but investors should weigh higher drawdowns against return potential.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
